Dr. Pinilla Alba on Safety Findings of the PARTNER Trial in Breast Cancer
Karen Pinilla Alba, MD, discusses the safety findings stages 1 and 2 of the phase II/III PARTNER trial in triple negative and/or germline BRCA-mutated breast cancer.
Related Articles
PATHFINDER 2 Trial Releases Positive Topline Data for Multicancer Early Detection Test
Galleri, a multicancer early detection test, demonstrated high positive predictive value and cancer detection in PATHFINDER 2.
Timing of ESR1 Mutation Testing Is Critical to Overcome Adaptive Endocrine Resistance in HR+ Breast Cancer
Kevin Kalinsky, MD, MS, FASCO, discusses how findings from SERENA-6 reinforce the importance of timely ESR1 testing in HR-positive breast cancer.
Dr Huppert on Evolving First-Line Treatment Standards for HER2+ Metastatic Breast Cancer
Laura Huppert, MD, discusses ways that the frontline use of T-DXd in HER2-positive metastatic breast cancer may affect later-line treatment decisions.
Adjuvant Dalpiciclib Plus Endocrine Therapy Improves iDFS in HR+/HER2– Early Breast Cancer
Adjuvant dalpiciclib plus endocrine therapy met the iDFS primary end point in the DAWNA-A trial in HR-positive, HER2-negative early breast cancer.
FELIX Analysis Highlights Factors Associated With Sustained Remission With Obe-Cel in R/R Acute Lymphoblastic Leukemia
Certain factors were associated with sustained remission with obe-cel in acute lymphoblastic leukemia.
Molecular Insights Guide First-Line and Post-Transplant Strategies in AML
Hetty E. Carraway, MD, MBA, discusses shifting treatment paradigms in AML from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.
Relacorilant Plus Nab-Paclitaxel Provides PFS Benefit in Platinum-Resistant Ovarian Cancer
Alexander B. Olawaiye, MD, discusses key efficacy and safety findings from ROSELLA trial and where the future is headed for studying relacorilant in PROC.
Mayo Clinic Researchers Link CAR-T Cell Aging to Cancer Relapse
Mayo Clinic researchers have discovered a key reason some patients with cancer relapse after receiving CAR T-cell therapy.
OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
FDA Receives Resubmitted BLA for Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease
The FDA received a BLA resubmission for tabelecleucel in EBV-positive post-transplant lymphoproliferative disease.